Reviewer's report

Title: Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study

Version: 2 Date: 6 February 2013

Reviewer: Jan Volavka

Reviewer's report:

There is one minor essential revision remaining: Figure 3 seems to show a huge difference between typicals and atypicals in persistence. This is probably due to the idiosyncratic way in which the authors defined persistence, i.e., staying within the same group (typical or atypical) while possibly switching among drugs within the group.

As shown in Fig 1, atypicals were used much more frequently than typicals. Thus, because of this bias, the patients on atypicals were more likely to be switched to other atypicals than to typicals.

This is then reflected as a great advantage in persistence favoring atypicals in Figure 3. But this is probably an artifact resulting from the authors' method of defining persistence.

The authors must address this in the Discussion, and clearly warn the reader that the apparent difference in persistence shown in Fig 3 cannot be compared with results of other authors who used a more conventional method to define persistence.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have no competing interest